User:Mr. Ibrahem/Mavacamten

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Mavacamten
Clinical data
Trade namesCamzyos
Other namesMYK-461
AHFS/Drugs.comMonograph
License data
Routes of
administration
By mouth
Drug classCardiac myosin inhibitor
Legal status
Legal status
Identifiers
  • 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
Chemical and physical data
FormulaC15H19N3O2
Molar mass273.336 g·mol−1
3D model (JSmol)
  • CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O
  • InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
  • Key:RLCLASQCAPXVLM-NSHDSACASA-N

Mavacamten, sold under the brand name Camzyos, is a medication used to treat hypertrophic obstructive cardiomyopathy (HCOM).[2] It is taken by mouth.[2]

Common side effects include dizziness and syncope.[2] Other side effects may include heart failure.[2] Use in pregnancy may harm the baby.[2] It is a cardiac myosin inhibitor.[2]

Mavacamten was approved for medical use in the United States in 2022.[2] It is not available in Europe or the United Kingdom as of 2022.[3] In the United States a month of medication costs about 7,800 USD.[4]

References[edit]

  1. ^ "Archive copy". Archived from the original on 2022-11-13. Retrieved 2022-11-29.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ^ a b c d e f g h i j "Camzyos- mavacamten capsule, gelatin coated". DailyMed. 28 April 2022. Archived from the original on 3 July 2022. Retrieved 15 May 2022.
  3. ^ "Mavacamten". SPS - Specialist Pharmacy Service. 19 October 2018. Archived from the original on 24 June 2022. Retrieved 12 December 2022.
  4. ^ "Camzyos Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 22 May 2023. Retrieved 12 December 2022.